Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer is a phase 3 interventional study registered as NCT03659448, led by Surgimab, and recruiting on the registry. Official title: Multicenter, Open-label, Randomised, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer. Planned enrolment is 300 participants (estimated). The study started in 2019-06-17 and primary completion is expected in 2024-11. No results have been posted on ClinicalTrials.gov.